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Aberrant soluble oligomers formed by the amyloid-β peptide (Aβ) are major pathogenic
agents in the onset and progression of Alzheimer’s disease. A variety of biomolecules can
influence the formation of these oligomers in the brain, although their mechanisms of action
are still largely unknown. Here, we studied the effects on Aβ aggregation of DOPAL, a
reactive catecholaldehyde intermediate of dopamine metabolism. We found that DOPAL is
able to stabilize Aβ oligomeric species, including dimers and trimers, that exert toxic effects
on human neuroblastoma cells, in particular increasing cytosolic calcium levels and pro-
moting the generation of reactive oxygen species. These results reveal an interplay between
Aβ aggregation and key biochemical processes regulating cellular homeostasis in the brain.
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A lzheimer’s disease (AD) is an untreatable neurodegen-erative disorder that affects over 50 million peopleworldwide1–4. If disease modifying treatments are not
found, the number of AD patients is expected to treble by 2050,
causing further tremendous human, social and economic impact
on our society1–5.
The aggregation of Aβ plays a central role in the cascade of
events leading to AD, such as loss of synaptic signalling, mito-
chondria dysfunction, increased production of reactive oxygen
species (ROS), neuroinflammation and ultimately, neuronal
loss2,6,7. At the molecular level, the aggregation process of Aβ
starts with the formation of soluble oligomeric species, which
further self-assemble into the mature and insoluble fibrils found
in the characteristic plaques1,3,8–10. Although Aβ plaques are a
major hallmark of AD, the severity of the pathology does not
correlate well with the extent of amyloid plaque formation11,12,
but rather with the amount of soluble Aβ oligomers13–21, which
are thought to be the most toxic species22–24. Recent studies have
reinforced this significance through the isolation of neurotoxic
dimers and other higher-order oligomeric assemblies from the
brains of patients14,25,26. Because such characterisation remains
challenging due to the transient and metastable nature of Aβ
oligomers in the brain23,27, many studies have attempted to sta-
bilise and characterise non-fibrillar species in order to improve
our understanding of oligomeric conformations and toxicity28–31.
As, however, these aggregates are mostly formed by artificial
means, it is important to further investigate their physiological
relevance. Moreover, in cellular environments many factors
contribute to, and interfere with, the aggregation of Aβ, thereby
further increasing the challenges in understanding the nature and
interactions of Aβ oligomers31–34.
Growing evidence shows that Aβ can be found not only in the
extracellular space but also in the luminal part of intracellular
compartments and organelles, such as the Golgi complex35,
endoplasmic reticulum and intermediate compartment36,37, and
mitochondrial membranes29,34. The build-up of intracellular Aβ
has been considered an early event in the development of the
pathogenesis of AD, and it is also observed in Down syndrome
individuals38–42. Thus, a multitude of different molecules, both in
the intracellular and extracellular spaces, can interact directly
with Aβ and affect its aggregation process by modifying its rate of
aggregation43,44, or redirecting the process towards the formation
of off-pathway toxic oligomeric species31. Dysregulations in the
homoeostasis of these molecules can generate imbalances in their
concentrations and activities, in turn altering the aggregation
processes31,32,43,45–47. Given the complex scenario in which Aβ
aggregation takes place, the unravelling of the interactions with
other molecules in the crowded intracellular and extracellular
spaces, and of the molecular pathways involved, is crucial for a
deeper understanding of the molecular origins of AD.
Well-established links exist between neurodegenerative and
metabolic disorders, including the observations of direct effects of
metabolite dyshomeostasis on synaptic dysfunction and increased
oxidative stress48–53. Excessive oxidative stress increases the
production of toxic and highly reactive aldehydes that are able to
interact promiscuously with proteins, resulting in a disruption of
protein homoeostasis and cellular damage52,54. The monoamine
oxidase (MAO) product of dopamine (DA), 3,4-dihydrox-
yphenylacetaldehyde (DOPAL), is one such aldehyde (Fig. 1),
which has previously been shown to induce toxicity in Parkin-
son’s disease by promoting oligomerisation of α-synuclein and
impairing the physiological function of synaptic vesicles (cate-
cholaldehyde hypothesis)55,56.
In this study, we show that DOPAL interacts with common
isoforms of Aβ (Aβ40 and Aβ42) and inhibits their fibril for-
mation, but not their oligomerisation process. Indeed, DOPAL
induces the formation of stable oligomeric species, including
dimers and trimers of Aβ40 (Aβ-DO), which possess a certain
degree of antiparallel β-sheet conformation. These oligomers
exert toxic activity in human neuroblastoma cell cultures,
including the induction of both calcium influx and the increase in
reactive oxygen species (ROS) production. These stabilised spe-
cies could resemble some populations of oligomers present in the
brain, and could offer a biologically relevant model system to the
study Aβ oligomers, which is otherwise challenging in on-
pathway oligomeric systems that are transient and more hetero-
geneous. Overall, our study suggests that DOPAL may act as an
intracellular co-neurotoxin in the pathophysiology of AD asso-
ciated with Aβ oligomers.
Results
DOPAL inhibits Aβ40 and Aβ42 fibril formation. DOPAL has
been found to interact with a range of proteins, including glu-
cocerebrosidase, ubiquitin and α-synuclein57. In particular, it has
been observed that DOPAL is able to covalently modify α-
synuclein by inducing the formation of α-synuclein oligomers
that do not tend to aggregate into cross-β fibrils54,55. However,
the effects of DOPAL on the aggregation of Aβ are yet to be fully
elucidated. To this end, using a highly sensitive chemical kinetics
assay based on thioflavin T (ThT) fluorescence, we monitored the
aggregation of Aβ40 in the absence and presence of DOPAL at
Aβ40-to-DOPAL ratios of 1:2, 1:5, 1:7, 1:10 and 1:15 molar
equivalents (Fig. 2). We observed that in the presence of DOPAL,
the half-time (t1/2) of the aggregation was increased as compared
to its absence. Furthermore, the final ThT fluorescence intensity,
which reflects the concentration of ThT-active fibrils at the end of
the reaction, was also decreased in the presence of DOPAL. Both
effects were found to be dependent on the concentration of
DOPAL (Fig. 2). Notably, in the presence of 2 molar equivalents
of DOPAL, we observe a 1.2 fold increase in t1/2 with a 2-fold
reduction in the final fluorescence intensity of the reaction, and in
the presence of 15 molar equivalents of DOPAL, the aggregation
was arrested entirely and no increase in ThT fluorescence was
observed (Fig. 2). Similar effects were also observed on the
aggregation of Aβ42, with a decrease in the endpoint ThT
fluorescence intensity, as well as an increase in the t1/2 of
aggregation (Fig. S1). Taken together, these results show that
DOPAL inhibits fibril formation of both Aβ40 and Aβ42.
Given that the inhibitory effect observed on Aβ fibril
formation underlines a molecular interaction between Aβ and
DOPAL, we explored whether or not DOPAL can stabilise
intermediate Aβ oligomeric species. Specifically, we focused on
studying the interaction of DOPAL with the Aβ40 isoform, as it is
the most abundantly produced isoform, and its relative
concentration with respect to Aβ42 is implicated in the pathology
of AD15,58. Aβ40 was incubated for 20 h in the absence and in the
presence of DOPAL and then subjected to centrifugation. In
order to avoid the interference of DMSO in our subsequent
analysis, further experiments and characterisation of oligomeric
species were performed using the pelleted sample where samples
could be resuspended in buffer to remove the traces of the DMSO
solvent, albeit similar species were also observed in the super-
natant fraction (Figs. 3a and S2). Through an SDS-PAGE
analysis, we found that in the absence of DOPAL, 35% of Aβ40
had converted into higher-order pelleted assemblies that could be
isolated by centrifugation. In the presence of DOPAL, while
approximately a similar 35% of Aβ40 had converted into higher-
order pelleted assemblies, we also observed the appearance of a
band at a molecular weight slightly above 8 kDa, suggesting the
formation of dimeric species in the pellet fraction. The band
intensity was observed to increase from about 5% to 15% (of the
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01490-3
2 COMMUNICATIONS BIOLOGY |            (2021) 4:19 | https://doi.org/10.1038/s42003-020-01490-3 | www.nature.com/commsbio
total intensity of all the bands) with increasing concentrations of
DOPAL, indicating a dose-dependent effect on the amount of Aβ
species formed at approximately 8 kDa (Fig. 3a).
DOPAL induces the formation of stable Aβ40 oligomers (Aβ-
DOs). We then investigated the morphologies of these Aβ40
aggregates using phase controlled and high-resolution atomic
force microscopy (AFM), which enables characterisation at the
single molecule scale and with angstroms resolution of monomers
and early oligomeric aggregates. We observed that both in the
absence and presence of DOPAL, aggregated samples of Aβ40
possessed similar cross-sectional heights in the order of 1–2 nm
(Fig. 3b). The Aβ-DOs have a spherical shape that is typical of
oligomeric intermediates27, whereas the aggregates formed in the
absence of DOPAL showed a tendency to elongate into species
that resemble early protofibrils (~1–2 nm cross-sectional height)
that would eventually form mature fibrils (~3–6 nm cross-
sectional height). A single molecule statistical analysis con-
firmed that the aggregated species in the presence of DOPAL
(Aβ-DOs, n= 154) were found to be significantly more spherical
(p < 0.001) as compared to the species formed in its absence (Aβ-
noDOs, n= 438) (Fig. 3b). These observations were further
substantiated when we assessed the stability of these oligomers
over the course of 40 h by ThT kinetics (Fig. 3c). Briefly, after
centrifugation, pellets formed in the absence (Aβ40-noDOs) and
presence of DOPAL (Aβ-DOs) were diluted to 10 μM, and their
stabilities were assessed by means of ThT fluorescence over the
course of 40 h at 37 °C. We observed that Aβ-noDOs eventually
proceeded to aggregate and convert into fibrils, resulting in an
increase in ThT intensity. Conversely, Aβ-DO species showed no
change in ThT intensities over time, suggesting a relatively higher
stability of these species at 37 °C in comparison to Aβ40-noDOs
(Fig. 3b). The transmission electron microscopy (TEM) analysis
on these samples obtained after 40 h of the stability measure-
ments confirmed the presence of mature fibrils in the aggregated
species of Aβ40 in the absence of DOPAL, and non-fibrillar
intermediate species in its presence (Fig. 3d). Thus, these results
suggest that unlike Aβ samples which typically aggregate to form
fibrillar species, the presence of DOPAL induces the formation of
spherical stable Aβ intermediates.
Aβ-DOs are characterised by an antiparallel β-sheet core and
low hydrophobicity. In order to further investigate the structural
features of the aggregated species formed in the presence of
DOPAL and, in particular, those at different molecular weights as
observed by SDS-PAGE (Fig. 2a), we performed size exclusion
chromatography (SEC) to evaluate the size distribution of the
species formed upon reacting with and without DOPAL for
comparison. Samples were boiled for 10 min with the addition of
0.1% SDS before injecting it onto the column to assess the dis-
tribution profile. We observed in the sample containing Aβ40
with DOPAL, the clear presence of higher-order species, in
addition to the monomer fraction. The eluted species between 8
and 13 ml corresponding to the presence of higher-order species
were, however, not present in the sample of Aβ40 without
DOPAL (Fig. 4a). In spite of the same volume and concentration
(monomer equivalents) injected into the column, we note the
diverse qualitative nature of the two SEC profiles: this difference
might be due to aggregated samples stuck at the pre-filter of the
column in the sample Aβ40-noDO, and the more heterogenous
nature of the samples Aβ40-DO responsible of the broad absor-
bance peaks. SEC profiles allow us to assess the presence of
higher-order species for Aβ-DO, but more sophisticated techni-
ques such as sedimentation velocity profiles are warranted to
Fig. 1 Schematic of the main metabolic pathway involving DOPAL. The catecholamine neurotransmitter dopamine is oxidised into the catecholaldehyde
DOPAL (3,4-dihydroxyphenylacetaldehyde) by monoamine oxidases (MAO), and further converted into the less toxic catecholic acid DOPAC (3,4-
dihydroxyphenylacetic acid) by aldehyde dehydrogenases (ALDH).
Fig. 2 DOPAL inhibits Aβ40 fibril formation in a dose-dependent manner. a Aggregation kinetics of Aβ40 in NaP pH 6.9, 0.2 mM EDTA in the absence
(empty circles) and presence (filled circles) of increasing molar equivalents of DOPAL (represented in different colours). b Normalised to control (absence
of DOPAL) half-time (t1/2) of aggregation (points) and end point fluorescence intensities (asterisks) as derived from the data in a. Throughout, error bars
represent means ± SEM of three replicates.
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accurately quantify such ensembles. As a further control, matrix-
assisted laser desorption/ionisation (MALDI) mass spectrometry
analysis of both samples without the addition of 0.1% SDS con-
firmed that while a dominant signal corresponding to 4462 Da
(Aβ(M1-40) monomer) was present in both Aβ40-noDO and Aβ-
DO samples, in the case of Aβ-DO, other signals corresponding
to higher-order species of dimers (8920, 8936 Da) and trimers
(13398 Da) could also be observed, which is otherwise much less
significant with respect to the Aβ40-noDO sample (Figs. S3 and
S4). These results also suggest that higher-order Aβ species
formed in the presence of DOPAL as observed in SDS-PAGE and
SEC were not artefactually induced by the presence of SDS. We
also observed from the molecular weight of the dimers and tri-
mers that the species formed are composed of Aβ alone and not
in complex with DOPAL, suggesting that oligomerisation may be
driven by non-covalent interactions with the metabolite (Fig. S3).
We then investigated the secondary structure of Aβ-DOs using
attenuated total reflection Fourier transform infrared (ATR-FTIR)
spectroscopy (Fig. 4b). Aβ-DOs showed a strong signal at
1625 cm−1, which correlates with a substantial presence of
intermolecular parallel β-sheet structure, and a strong signal at
1693 cm−1, which indicates the presence of antiparallel β-sheet
structure59. The antiparallel β-sheet structure has been reported as a
characteristic of both Aβ40 and Aβ42 oligomeric species60–62. This
was further confirmed by comparing the FTIR spectrum of Aβ-DOs
with fully formed Aβ40 fibrils, where we only observed a parallel β-
sheet peak at 1627 cm−1. Thus, the secondary structures of Aβ-DOs
and Aβ40 fibrils are different. In addition, we also validated the
content of solvent-exposed β-sheet structure of Aβ-noDOs via a
ThT assay (Fig. 4c). After 20 h of incubation, we observed that
Aβ40 samples in the absence of DOPAL exhibited a higher ThT
fluorescence signal (15-fold increase) as compared to Aβ40 samples
in the presence of DOPAL (5-fold increase), thus indicating a lower
content of solvent-exposed β-sheet content in the latter sample.
This observation could also be attributed to the higher amounts of
fibrillar content in Aβ-noDOs as compared to the oligomeric
samples of Aβ-DOs. We also sought to assess the hydrophobicity of
the Aβ40 samples, which is considered as a key determinant feature
of oligomers27. This assessment was performed by measuring the
fluorescence change in the dye 8-anilinonaphthalene-1-sulfonic-
acid (ANS). Upon binding to hydrophobic surfaces, ANS generates
an increase in fluorescence and a blue-shift of its maximum
emission peak wavelength63. While Aβ-noDOs showed an
approximately 2-fold increase in the fluorescence intensity when
compared to the control and a blue-shift of its maximum
wavelength, Aβ-DOs caused only a slight blue-shift and a small
increase in fluorescence emission (Fig. 4d). Taken together, these
results show that Aβ-DOs are oligomeric with a core β-sheet
structure, with low content of β-sheet and hydrophobic patches
exposed to the solvent.
Aβ-DOs are toxic to human neuroblastoma cells. Aβ oligomers
are known to cause toxicity to cells, including by enhancing the
production of ROS, disrupting Ca2+ influx and promoting
mitochondrial dysfunction31,64,65. Thus, we evaluated the ability
of Aβ-DOs to cause cellular dysfunction to human SH-SY5Y cells
using three different assays, the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction test, the mea-
surement of Ca2+ influx and the detection of ROS production.
Fig. 3 Biophysical characterisation of DOPAL-induced stable Aβ40 oligomers (Aβ-DOs). a SDS-page analysis of the pellet fraction of Aβ40 after 20 h of
incubation with increasing concentrations of DOPAL. b–d Morphologies and stability measurement of Aβ40-noDOs and Aβ-DOs. b Representative 3D
morphology maps measured by AFM of preformed Aβ40-noDOs and Aβ-DOs, with their cross-sectional height and roundness distributions as collected
from a. c ThT-based stability measurements of Aβ40-noDOs and Aβ-DOs over the course of 40 h. d TEM images of the samples in b, after 40 h of
incubation at 37 °C. Note the distinct fibrillised samples of Aβ40-noDOs after the stability measurement, which is otherwise absent in the Aβ40-DOs
samples. For figures b, c and d, assays were performed using the sample containing 10 molar equivalents of DOPAL.
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Firstly, we evaluated viability of the SH-SY5Y cells after 24 h of
treatment with Aβ incubated in the presence or in the absence of
DOPAL. The MTT test indicated that the cellular dysfunction
following the treatment with Aβ-DOs increased. The viability of
the cells decreased in 33 ± 6% in the presence of 0.1 μMAβ-DO
and reached the highest decrement of 47 ± 5% at 5 μM. The
treatment of the cells with 7 µM Aβ-DO was found to cause a
significantly different toxic effect compared to the untreated, but
not to increase further this signal, in line with previously
published data showing that the toxicity of the oligomers
correlates non-linearly with their concentration66 (Fig. 5a). Since
DOPAL alone did not induce significant toxicity, the toxicity
observed could thus be attributed to the presence of Aβ-DOs
(Figs. 5a, S6 and S7). In contrast, although Aβ-noDOs showed
toxicity, the decrease in cell viability was only significant at the
highest concentration tested (Fig. 5b). To get insight into the
biological events occurring at the early stages after the treatment,
we evaluated the Ca2+ influx and the ROS production in cells
upon exposure to Aβ40-noDOs and Aβ-DOs. The cells treated
with Aβ-DOs showed a significant increase in fluorescence after
40 min of treatment, indicating Ca2+ influx into the cells, whereas
cells treated with Aβ40-noDOs did not show a significant increase
(Fig. 5c, d). Following the addition of Aβ-DOs to the cells a
significant increase in fluorescence was observed over time,
reflecting an increased production of ROS triggered by Aβ-
DOs (Fig. 5e, f). Conversely, cells exposed to Aβ40-noDOs did
not display a significant ROS production (Fig. 5e, f). Overall, we
could observe significant toxicity to neuroblastoma cells caused
by the exposure to Aβ-DOs, which manifests in the reduction of
cell metabolic activity (MTT test), increase in Ca2+ influx, and
increase in ROS production. We note that these effects are
comparable to previous reports, where oligomeric species of Aβ
and α-synuclein were shown to cause an increase in ROS
production, as well as cellular toxicity, though it is possible that
other toxicity mechanisms may also account for the overall
cytotoxic activity of the oligomers, including unspecific interac-
tions with membrane receptors, such as NMDA and AMPA
receptors16,17,24,31.
Discussion
Oligomeric species of Aβ are closely implicated in the patho-
physiology of AD13–17 and have been found in brain extracts18,19
and cerebrospinal fluid of AD patients20. Recently, cross-linked
Aβ dimers found in brain tissue of AD patients were shown to be
toxic towards induced pluripotent stem cell (iPSC)-derived neu-
rons26. Furthermore, Aβ dimers were found to directly induce
hyperphosphorylation of tau22, and to impair learning and
synaptic plasticity in mice, even in the absence of amyloid pla-
ques21, suggesting that such species may play a critical role in the
early stages of the disease.
Although the presence of Aβ dimers and other higher order
species has been reported by several groups, and their causative
role in the pathophysiology of AD is well accepted13,14,16–21, the
physiological mechanism of their formation still remains unclear.
Here, we have observed that DOPAL, an endogenous brain
metabolite, leads to the formation of stable neurotoxic oligomers
of Aβ40, unveiling possible interactions between metabolites and
proteins within the crowded and complex cellular environment.
In fact, since physiological concentrations of DOPAL are in
excess with respect to that of Aβ, such a mechanism of higher
stoichiometry of DOPAL-to-Aβ can also manifest in vivo9,67–69.
Fig. 4 Size distribution and structural characterisation of Aβ-DOs. a Size-exclusion chromatography profiles of Aβ40-noDOs (black line) compared to
Aβ-DOs (red line). b Second derivative of ATR-FTIR spectra of Aβ40 fibrils (black line) and Aβ-DOs (red line). c Fluorescence emission spectra of ThT in
the absence (green), or in the presence of Aβ40-noDOs (black) or Aβ-DOs (red). d Fluorescence emission spectra of ANS in the absence (green), or in the
presence of Aβ40-noDOs (black) or Aβ-DOs (red).
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Substantial evidence correlates a rise in levels of DOPAL with
different pathological processes, such as mitochondrial dysfunc-
tion and oxidative stress52. It has been shown that aberrant oxi-
dative stress can lead to a build-up of DOPAL, by catalysing
dopamine oxidation and blocking the further catabolism of
DOPAL into less toxic metabolites6. Furthermore, mitochondrial
dysfunction and oxidative stress can be induced by several neu-
rological diseases including AD, depression and anxiety dis-
orders70–74. Hence, we propose a molecular mechanism where an
abnormal build-up of DOPAL can lead to the stabilisation of
toxic dimers and other oligomers of Aβ, initiating an early cas-
cade of events that may contribute to the pathophysiology of AD
(Fig. 6). Indeed, while homeostatic control allows for the presence
of biological factors such as molecular chaperones to inhibit the
aggregation of Aβ as a means of reducing toxicity, homoeostatic
dysregulation can lead to the build-up of other metabolites, such
as DOPAL, which can further trigger the toxicity cascade in the
overall pathology of the disease. In this view, this mechanism
illustrates how the inhibition of the fibril formation could lead to
deleterious effects if associated to the stabilisation of intermediate
species, and how reactive metabolic intermediates can influence
early events in the development of AD. Understanding these
mechanisms can lead to new approaches in prevention and






































































































Fig. 5 Aβ-DOs are toxic to neuroblastoma cells. a Cell viability determined by the MTT reduction test in cells exposed to increasing concentrations of Aβ-
DOs. b Intracellular Ca2+ influx associated fluorescence upon 40min of treatment with buffer (light green), Aβ40-noDOs (green) or Aβ-DOs (dark green).
F/F0 is the ratio between the Ca2+ influx-derived fluorescence intensity in the presence (F) and absence (F0) of Aβ aggregates. c Representative images of
intracellular Ca2+ influx upon 40min treatment with buffer (left), Aβ40-noDOs (centre) or Aβ-DOs (right). d Kinetics of ROS production of cells at 37 °C
either in the absence or in the presence of Aβ40-noDOs or Aβ-DOs. e F/F0 ratio between the ROS-derived fluorescence intensity in the presence (F) and
absence (F0) of Aβ40-noDOs (green) and Aβ-DOs (dark green) at 10 h; the untreated control is shown in orange. Positive control of 0.01% H2O2 is shown
in grey. For the MTT test, error bars represent means ± SEM of five replicates. For calcium influx and ROS production, error bars represent means ± SEM of
three replicates. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001 relative to untreated cells are shown.
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Methods
Production of Aβ40 and Aβ42 peptides. Recombinant Aβ(M1-40)
(MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV), here called
Aβ40, and Aβ (M1-42) (MDAEFRHDSGYEVHHQKLVFFAEDVGSNK-
GAIIGLMVGGVVIA), here called Aβ42, were expressed and purified using a
method previously described10. In particular, Aβ(M1-40) has been shown to
aggregate and adopt a similar fibril structure as Aβ(1-40)75. Briefly, Escherichia coli
BL21-Gold (DE3) (Stratagene, La Jolla, CA) expressing the peptides were sonicated
and inclusion bodies were dissolved in 8 M urea, followed by anion exchange in
batch mode using diethylaminoethyl cellulose resin and lyophilisation. Combined
lyophilised fractions were further purified using a Superdex 75HR 26/60 column
(GE Healthcare, Chicago, IL) and eluates were analysed using SDS–polyacrylamide
gel electrophoresis NuPAGE 4–12% Bis-Tris for the presence of the desired protein
product. The fractions containing the pure peptide were lyophilised again and
stored in −80 °C.
Preparation of Aβ40 and Aβ42 for kinetic experiments. Solutions of Aβ40 and
Aβ42 were prepared by dissolving the lyophilised Aβ40 or Aβ42 in 6M guanidi-
nium hydrochloride (GnHCl). Monomers were separated from salt and potential
fibrillar or oligomeric species using a Superdex 75 Increase 10/300 GL column (GE
Healthcare) at a flow rate of 0.5 mL/min, eluted in 20 mM sodium phosphate
buffer, pH 6.9 (Aβ40) and pH 8 (Aβ42), supplemented with 200 μM EDTA. The
peak corresponding to the monomer fraction was collected and the concentration
of the peptide was determined by the absorption of the integrated peak area using
ε280= 1490 l mol−1 cm−1. The resulting monomer solution was diluted with the
respective buffer used in the purification to the desired concentrations and sup-
plemented with 20 μM ThT. Samples were then incubated in the absence or pre-
sence of different molar equivalents of DOPAL (3,4-dihydroxyphenylacetaldehyde)
(ChemCruz, Dallas, TX), which were prepared from a stock concentration of 200
mM, and then pipetted into multiple wells of a 96-well half-area, low-binding, clear
bottom and PEG coated plate (Corning 3881), 80 µL per well.
Preparation of Aβ40 oligomers. Aβ40 oligomers were prepared as described
previously31. To generate the Aβ40 oligomers, 0.5 mg of lyophilised peptide was
dissolved in 300 μL hexafluoro-2-isopropanol (HFIP), incubated overnight at 4 °C,
and dried under a gentle N2 flow to evaporate the HFIP. The peptide was resus-
pended in 50 μL DMSO, sonicated for 10 min at room temperature, diluted in
sodium phosphate buffer, at pH 6.9, in the absence or presence of different con-
centrations of DOPAL to a final concentration of 100 μM, and incubated at 20 °C
for 20 h in a final volume of 275 μL. After the reaction, the oligomeric fractions
were isolated via centrifugation at 15,000 rpm for 20 min at 20 °C, and resuspended
in 275 μL to a final concentration of 35 μM (as determined from SDS-PAGE).
Aβ40 oligomers stability assay. After 20 h of incubation, samples containing
Aβ40 (10 μM monomer equivalent) in the absence and presence of 10 molar
equivalents of DOPAL were added to a 20 μM ThT solution and further incubated
in a plate reader at 37 °C for 40 h. The fluorescence intensity was recorded using an
excitation 440 nm and emission 480 nm wavelenghts with a plate reader ClarioStar
(BMG Labtech, Aylesbury, UK).
Atomic force microscopy (AFM). After 20 h of incubation, samples containing
Aβ40 (35 μM monomer equivalents) in the absence or presence of 10 molar
equivalents of DOPAL were diluted to 0.5 μM (monomer equivalents), then
deposited on freshly cleaved mica substrates using AFM. Ten microlitre diluted
samples were deposited on the substrate at room temperature. The samples were
incubated for 10 min, followed by rinsing with 1 mL milliQ water. Then the
samples were dried using a gentle flow of nitrogen gas. AFM maps of 3D mor-
phology of all the samples were acquired in the regime of constant phase change,
with 2 nm/pixel resolution using a NX10 (Park Systems, city, South Korea) oper-
ating in non-contact mode76. This set-up was equipped with a silicon tip with a
nominal radius of <8 nm and spring constant of 5 N/m (PPP-NCHR).
Scanning Probe Image Processor (SPIP) (Image Metrology, Denmark) software
was used for image flattening and single aggregate statistical analysis. The average
level of noise for each image is in the order of <0.1 nm, as demonstrated by
roughness measurements77,78. All the measurements were performed at room
temperature.
Transmission electron microscopy (TEM). After the oligomer stability mea-
surement, samples containing Aβ40 in the absence and presence of 10 molar
equivalents of DOPAL were diluted to 2 μM (monomer equivalents), and prepared
on 400-mesh, 3-mm copper grid carbon support film grids (EM Resolutions Ltd.,
Sheffield, UK) and stained with 2% (w/v) uranyl acetate solution. Salts and excess
uranyl acetate were washed by rinsing with deionized water (Milli-Q) and dried at
RT over 10 min. Imaging was carried out using the FEI Tecnai G2 transmission
electron microscope (Cambridge Advanced Imaging Centre (CAIC) University of
Cambridge, UK), and the images were acquired using the SIS Megaview II Image
Capture system (Olympus, Muenster, Germany).
Size exclusion chromatography. Separation of different Aβ40 species in the
presence or absence of 10 molar equivalents of DOPAL after 20 h of incubation was
obtained by gel filtration using a SuperdexTM 75 10/300 GL column (GE Health-
care) connected to an ÄKTAprime (GE Healthcare) system. The column was
equilibrated with phosphate buffer pH 6.9 and the elution was followed at a flow
rate of 0.5 ml/min. The absorbance was measured at 280 nm.
Fourier transform infrared spectroscopy (FTIR). Oligomeric samples of
Aβ40 stabilised with 10 molar equivalents of DOPAL, as well as fibrillar samples of
Aβ40 were centrifuged and the pellets resuspended in 12 μL of phosphate buffer at
pH 6.9 to a concentration of 2.6 mM (monomer equivalent of protein). Attenuated
total reflection FTIR (ATR-FTIR) spectroscopy was performed using a Bruker
Vertex 70 spectrometer with a diamond ATR element (Bruker, Billerica, MA). The
spectra were acquired with a resolution of 4 cm−1 and processed using the Bruker
software. Four spectra were averaged (each spectrum obtained from 128 scans),
and the second derivative was calculated using a Savitzky−Golay filter (2nd order,
12 points).
ThT endpoint binding assay. After 20 h of incubation, samples containing Aβ40
(10 μM monomer equivalent) in the absence and presence of 10 molar equivalents
Fig. 6 DOPAL dysregulation hypothesis of Aβ oligomerisation. A dysregulation in DOPAL homeostasis and a consequent build-up of DOPAL can lead to
the stabilisation of toxic intracellular oligomers of Aβ. This phenomenon leads to cellular damage and further oxidative stress.
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of DOPAL were added to solutions of ThT in phosphate buffer at pH 6.9 to a final
concentration of 20 μM ThT. The emission spectra of excitation for ThT (440 nm)
were acquired at 25 °C using the plate reader ClarioStar (BMG Labtech, Aylesbury,
UK). Samples were analysed from two independent preparations and results show
an average of 40 scans for each sample.
ANS binding assay. After 20 h of incubation, samples containing Aβ40 (10 μM
monomer equivalent) in the absence or presence of 10 molar equivalents of
DOPAL were added to solutions of 8-anilinonaphthalene-1-sulfonic-acid (ANS) in
phosphate buffer at pH 6.9 to obtain 3-fold excess of ANS. The emission spectra of
excitation for ANS (380 nm) were acquired at 25 °C using the plate reader Clar-
ioStar Omega (BMG Labtech, Aylesbury, UK). Samples were analysed from two
independent preparations and results show an average of 40 scans for each sample.
Cell cultures. Human SH-SY5Y neuroblastoma cells (A.T.C.C., Manassas, VA)
were cultured in Dulbecco’s Modified Eagles Medium (DMEM)/F12+GlutaMax
supplement (Thermo Fisher Scientific, Waltham, MA) with 10% heat-inactivated
foetal bovine serum. The cell cultures were maintained at 37 °C in a 5.0% CO2
humidified atmosphere and grown until 80% confluence for a maximum of 20
passages.
MTT reduction assay. Cell viability was measured using the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Cells were
transferred to into a 96-well plate and treated for 24 h with samples containing
Aβ40 in the absence or presence of 10 molar equivalents of DOPAL after a 20 h
incubation. The cells cultures were then incubated with 0.5 mg/mL MTT solution
at 37 °C for 4 h, followed by the addition of cell lysis buffer (20% SDS, 50% N,N-
dimethylformamide, pH 4.7) for 3 h. Absorbance values of blue formazan were
measured at 590 nm using a plate reader (ClarioStar Omega BMG Labtech,
Aylesbury, UK), and cell viability was expressed as the percentage of MTT
reduction in treated cells as compared to untreated cells (taken as 100%).
Ca2+ influx assay. Cytosolic calcium ions (Ca2+) levels were measured by
exposing the SH-SY5Y cells loaded with 2.0 μM Fluo4-AM (Thermo Fisher Sci-
entific, Waltham, MA) to samples containing Aβ40 in the absence or presence of
10 molar equivalents of DOPAL after a 20 h incubation. The emitted fluorescence
of Fluo4 was recorded after excitation at 488 nm using the fluorescence microscope
Cytation5 Cell Imaging Reader and quantified by means of the Gen5 Data Analysis
software (BioTek Instruments, Winooski, VT).
Measurement of ROS production. ROS production was measured using the
Fluorometric Intracellular ROS kit MAK143 (Sigma-Aldrich, St. Louis, MO) fol-
lowing the manufacturer’s protocol. Briefly, SH-SY5Y cells were seeded in black
polystyrene 96-well plates for 24 h, followed by treatment with 1 μM of samples
containing Aβ40 in the absence or presence of 10 molar equivalents of DOPAL
after a 20 h incubation. The ROS production was monitored over time exploiting
the fact that ROS species react with a fluorogenic sensor in the cytoplasm, resulting
in a fluorometric product whose amount is proportional to the amount of ROS
present. We thus measured the emission of fluorescence at 520 nm (excitation at
490 nm) at 37 °C using a plate reader (BMG Labtech, Aylesbury, UK).
Statistics and reproducibility. For cellular assays, comparisons between groups
were performed using the one-way ANOVA followed by Bonferroni’s multiple
comparison test. A p-value lower than 0.05 was considered statistically significant.
*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data generated or analysed in this study are included in the article and supporting
information. All data are available from the authors upon reasonable request. All data
generated or analysed during this study are included in this published article (and
its supplementary information files).
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